NO961547D0 - Flavinderivater som anti-virusmidler - Google Patents

Flavinderivater som anti-virusmidler

Info

Publication number
NO961547D0
NO961547D0 NO961547A NO961547A NO961547D0 NO 961547 D0 NO961547 D0 NO 961547D0 NO 961547 A NO961547 A NO 961547A NO 961547 A NO961547 A NO 961547A NO 961547 D0 NO961547 D0 NO 961547D0
Authority
NO
Norway
Prior art keywords
viral agents
flavin derivatives
flavin
derivatives
viral
Prior art date
Application number
NO961547A
Other languages
English (en)
Other versions
NO961547L (no
Inventor
Washington Odur Ayuko
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of NO961547D0 publication Critical patent/NO961547D0/no
Publication of NO961547L publication Critical patent/NO961547L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO961547A 1993-10-19 1996-04-18 Flavinderivater som anti-virusmidler NO961547L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents
PCT/GB1994/002292 WO1995011028A1 (en) 1993-10-19 1994-10-19 Flavin derivatives as anti-viral agents

Publications (2)

Publication Number Publication Date
NO961547D0 true NO961547D0 (no) 1996-04-18
NO961547L NO961547L (no) 1996-06-19

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961547A NO961547L (no) 1993-10-19 1996-04-18 Flavinderivater som anti-virusmidler

Country Status (26)

Country Link
EP (1) EP0739208A1 (no)
JP (1) JPH09505804A (no)
CN (1) CN1140992A (no)
AP (1) AP620A (no)
AU (1) AU7943794A (no)
BG (1) BG100599A (no)
BR (1) BR9407862A (no)
CA (2) CA2123825A1 (no)
CO (1) CO4520283A1 (no)
CZ (1) CZ113796A3 (no)
EE (1) EE9600057A (no)
GB (2) GB9321558D0 (no)
HR (1) HRP940688A2 (no)
HU (1) HUT76322A (no)
IL (1) IL111338A0 (no)
JO (1) JO1866B1 (no)
MA (1) MA23356A1 (no)
MD (1) MD960168A (no)
NO (1) NO961547L (no)
OA (1) OA10579A (no)
PE (1) PE5596A1 (no)
PL (1) PL314008A1 (no)
SK (1) SK50696A3 (no)
UY (1) UY23844A1 (no)
WO (1) WO1995011028A1 (no)
ZA (1) ZA948191B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
WO2004043338A2 (en) * 2002-05-10 2004-05-27 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
WO2004013142A1 (fr) * 2002-08-02 2004-02-12 The Institute Of Radiation Medicine, Academy Of Miilitary Medical Sciences, People's Liberation Army Derive de riboflavine ainsi que sa fabrication et ses utilisations
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
MX2020004211A (es) * 2017-10-24 2020-08-13 Lunella Biotech Inc Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial.
KR20220034163A (ko) * 2019-07-09 2022-03-17 디에스엠 아이피 어셋츠 비.브이. 엘라피브라노와 리보플라빈 또는 dha의 바이러스 활성 감소

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
AU3222893A (en) * 1991-11-25 1993-06-28 University Of Michigan, The Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
PE5596A1 (es) 1996-04-18
AP9400695A0 (en) 1995-01-31
BR9407862A (pt) 1997-05-20
CA2174552A1 (en) 1995-04-27
ZA948191B (en) 1995-06-08
NO961547L (no) 1996-06-19
JPH09505804A (ja) 1997-06-10
AU7943794A (en) 1995-05-08
CN1140992A (zh) 1997-01-22
CO4520283A1 (es) 1997-10-15
AP620A (en) 1997-10-14
EE9600057A (et) 1996-10-15
MD960168A (ro) 1998-04-30
GB9421099D0 (en) 1994-12-07
WO1995011028A1 (en) 1995-04-27
GB2283913A (en) 1995-05-24
HRP940688A2 (en) 1997-04-30
UY23844A1 (es) 1995-03-28
OA10579A (en) 2002-06-19
BG100599A (en) 1997-02-28
HU9601006D0 (en) 1996-06-28
CA2123825A1 (en) 1995-04-20
HUT76322A (en) 1997-08-28
PL314008A1 (en) 1996-08-05
CZ113796A3 (en) 1996-11-13
GB9321558D0 (en) 1993-12-08
IL111338A0 (en) 1994-12-29
JO1866B1 (en) 1995-12-27
MA23356A1 (fr) 1995-07-01
EP0739208A1 (en) 1996-10-30
SK50696A3 (en) 1997-01-08

Similar Documents

Publication Publication Date Title
IS4208A (is) 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
KR960701052A (ko) 피롤로-피리딘 유도체(Pyrrolo-pyridine derivatives)
DK1028961T3 (da) Pleuromutilinderivater som antimikrobielle midler
DK0516349T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
NO960371D0 (no) Piperazinderivater som ter
FI940574A (fi) Bentseenisulfonamidijohdannaiset herbisideinä
NO903863L (no) Tiazolidindionderivater som hypoglykemiske midler.
KR960703888A (ko) 이소플라본 유도체 (isoflavone derivatives)
NO961547D0 (no) Flavinderivater som anti-virusmidler
FI933022A0 (fi) Radiosystem som bildar en traodloes lokalslinga
DE59402621D1 (de) Fluor-trifluormethylbenzoesäure-Derivate
FI972585A0 (fi) Virustenvastaisina aineina käyttökelpoiset tienoksatsinonijohdannaiset
DK0660715T3 (da) Carbostyrilderivater som antiarytmiske midler
DE69425117D1 (de) Fluorierte Diazabicycloalkanderivate
DE59407726D1 (de) 3-Aryl-4-hydroxy-3-dihydrofuranon-Derivate
ITMI941191A0 (it) 1-b-metil-2-tiol carbapen derivati
NO950327D0 (no) Pyridoindolobenzodiazepiner og derivater som antipsykotiske midler
FI962010A (fi) Immuunivastetta heikentävinä aineina käytettäviä 6-okso-nukleosideja
TR27956A (tr) Hidroksietil-azolil türevleri.
KR960700235A (ko) 신규 치환 티오세미카르바존 유도체(Novel Substituted Thiosemicarbazone Derivatives)
DE69400388D1 (de) Cyclohexendiolderivate
NO950061D0 (no) 4-oksa-1-azabisyklo [3,2,0Å heptan-7-on-derivater som antitumormidler
NO951299D0 (no) Polyaminderivater som anti-cytomegalovirale midler
DK12193D0 (da) Legetoej udformet som byggesaet
SE9302444D0 (sv) Vitamin composition